Oncolytics Biotech Inc T.ONC

Biogen’s $7.3 Bln acquisition of Reata followed bidding war

[Noteable]

Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals — its first major deal in more than four years — came after a showdown with another potential buyer and saw the acquisition price pushed up from $140 a share to $172.50, according to a securities filing.

https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/

[Noteable]

So Biogen paid US$7.3 Billion for a niche product Biopharmaceutical company. Now think about why ONCY is worth US$10+ Billion and more with 2 Phase 3 ready clinical trials in orphan / rare disease indications with unmet medical needs. Enhertu  is still not indicated for HER2- mBC - just low HER2.

[fox7mf]

Agreed Note. The information Oncy advanced that more BPs are interested since ASCO was just what the Dr ordered. Something that they obviously can't divulge is going on. Who was the institution that took up most of the $15m bought deal? Sept & Oct will be exciting & could bring the long awaited acquisition of Oncy.

[Journeytc]

I hope the institution takes a board position.    Someone with vested interest "shares" on the board most welcome. 

[Angler101]

No truer hopes ever spoken...i think that's the next nr we'll see

[Noteable]

- And this - 

[Noteable]

https://www.fiercepharma.com/pharma/how-biogen-outbid-rival-pharma-claim-reata-its-own-73b

[Noteable]

Here's some further reality  ..Biogen paid US$7.3 Billion for a niche product Biopharmaceutical company. Now think about why ONCY is worth US$10+ Billion and more with 2 Phase 3 ready clinical trials in orphan / rare disease indications with unmet medical needs. Enhertu  is still not indicated forER+/ HER2- mBC - just low HER2 and an Accelerated Approval for pelareorep in mBC can

[Noteable]

Repost - Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals — its first major deal in more than four years — came after a showdown with another potential buyer and saw the acquisition price pushed up from $140 a share to $172.50, according to a securities filing. https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/

[canadafan]

ONC/Ys potential value, vs trading price. Most who tak the time to understand, including the PanCan people who put up $5Million towards an additional arm of Pancratic cancer. And Roche who will be co-therapy in the Pahse 3 trial ( Panc cancer) ...have done massive due dilligence before geting to this stage. The existin trading price has little to zero semblance to ultimate "value" 1. The

[Noteable]

Reality Check - Big Pharma is in a bidding war for late-stage biological assests.

[Noteable]

And if you don't think so - then why are you here?

[Noteable]

Interesting since China's foreign ministry spokesman Wang Wenbin threateningly told media on Wednesday "They will eventually be slapped in the face by reality," he said.  Really??  One has to ask whether it is the kind of reality touted by this board's 60's comedy crowd

[13X2413]

Who cares?

[Buckhenry]

Unnoteable... we all wish you and Wang were wite... but we have lived the reality of this POS  for many years. 

[venture009]

Agreed BH. Over the years we have had those with an over abundance of enthusiasm predicting the money only to be followed a collapse in sp and nothing to take us to any meaningful value. However, with 2 PIII and successes with coloretal cancer , mm, maybe Noteable's prediction will be correct. One thing that would serve to amplify the potential is the FDA to grant us the AA to start the ball

[westcoast1000]

ONCY would have to apply in concert with its collaborators to get AA, which could occur after they have a P 3 in place. 

[Buckhenry]

I think many of us are just tired of reading the same Ole regurgitated rhetorical stuff that was posted years ago. There is just really not to much to say at this point that has not been said and everybody has known. Everyone is just guessing.  That and 3 bucks will get you coffee  at Starbucks. Remember. The beatings will continue until moral improves. 

[westcoast1000]

Adding to my previous post, They have discussed an 80 patient run in trial on panc. If it works as expected, that is when I would guess that an AA designation would be pursued. But no one knows. 

[Noteable]

And Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals came after a showdown with another potential buyer that turned into a bidding war for Reata Pharma's biological assets.